p256-AQP2 was markedly decreased in both groups receiving Tolvaptan (CKD + T and T), being barely detectable in the T group, where p256-AQP2 was less expressed than in the C group and CKD+T group (Fig 6). The gene discussed is AQP2; the disease is chronic kidney disease.